Drug firm optimistic
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.BRITISH Bio-technology, the drug research company that came to the market at the start of this month, reported 'excellent progress' along with an pounds 11.6m loss in its debut results announcement, writes Paul Durman.
Bio-technology companies, which use molecular biology to develop new drugs, typically incur heavy losses in their early years until the uncertain date when they can license a saleable product.
British Bio-technology, the first such company to come to the UK market, is about to begin human testing of an asthma treatment that is unlikely to come to the market for five years. Under the terms of a recent deal, the drug giant Glaxo has agreed to bear the costs of testing the effectiveness of the company's compound. If the product is successful, these costs could be as much as pounds 20m.
British Bio-technology has also begun initial testing of a vaccine that retards the development of Aids in people who are HIV-positive, and a cancer treatment.
The company's pounds 30m placing has left it with pounds 60m on deposit.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments